Signs positive for biotech deal activity in 2010
This article was originally published in Scrip
If the activity seen in late December is anything to go by, 2010 could be a bumper year for deal-making, particularly in biotech. December was a busy month, with a raft of new, mostly biotech-related deals involving big pharma. Companies including Teva, AstraZeneca Pfizer, Lilly and GSK announced deals worth over $2 billion in total.
You may also be interested in...
Siemens Healthineers Adds Muscle To Global Antibody Testing Effort, In Talks With Vaccine Developers
The company now has US emergency use designation for its new SARS-CoV-2 test, which can run on its global installed base of 20,000 analyzers at a current capacity of 50 million tests per month.
The test, made by Fujirebio, will help Japan to reach its 400,000-per-week COVID-19 test target.
The company says the serology test has a specificity of 99.8% and sensitivity of 100%